Compare Citius Pharmaceuticals Inc (CTXR) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs IAC/Interactivecorp — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while IAC/Interactivecorp trades at $40.21 (market cap $3.03B). The key difference: IAC/Interactivecorp is far larger — about 161.8× Citius Pharmaceuticals Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | PPLI | |
|---|---|---|
Market Cap | $18.73M | $3.03B |
Sector | Health | Media |
52-Week High | $1.82 | $47.62 |
52-Week Low | $0.48 | $31.52 |
Enterprise Value | $14.95M | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
People Incorporated (PPLI) trades at $41.58, down 3.17% amid bearish technical signals despite strong Q2 2026 earnings beat. The company shows mixed fundamentals with attractive valuation ratios (P/E 7.04, P/B 0.61) but volatile profitability trends. Recent news highlights digital revenue growth, corporate restructuring, and MGM investment gains, while institutional activity shows mixed positioning with Amundi increasing stake by 397.4% in Q2 2026.
PPLI presents a value opportunity with deep discount to analyst consensus target of $60.50 (45% upside), though investors face execution risks from restructuring and inconsistent earnings history. The stock's near-term direction hinges on successful asset monetization and sustained digital growth against backdrop of negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
